DUBLIN, June 23, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Key Pharma News Issue 52" report to their offering.
The current unmet medical need in influenza treatment creates a favourable commercial environment for MedImmune to enter. The US ageing population creates a sustained and growing patient base that will serve to drive considerable growth for effective anti-influenza medications. The introduction of a universal flu vaccine would serve to cap sales considerably, but development is still in its infancy.
Key Topics Covered:
1. Agreements
- Innovation And Differentiation Will Drive Change For GSK
2. Corporate Activity
- Towards Harmonising Transatlantic Review Times
- Sanofi/Merck To End European Joint Vaccines Operations
- Teva Acquisition Of Allergan Generics Edges Closer With Key European Approval
3. Product News
- Fast-Paced Treatment Optimisation Will Continue To Drive Up Cancer Drug Spend
- Pfizer's Xalkori Granted FDA Approval For ROS1-Positive Metastatic NSCLC
- Celgene Receives Paclitaxel ANDA Notice
- More Work Necessary For WHO To Break Biosimilar Naming Stalemate
- Novel CF Drug Will Secure Market For Vertex Despite High Cost
- Teva Canada Launches Abacavir+Lamivudine
4. R&D
- Zydelig Woes Underscore Need For Scale-Up In Diversification Efforts
- CNS Breakthroughs Slowing Despite Increasing Demand
- Idelvion Approval Will Bolster CSL Behring's Rare Disease Portfolio
For more information visit http://www.researchandmarkets.com/research/q7s47t/key_pharma_news
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article